Neil Riordan, PhD Presents at American Academy of Anti-Aging Medicine's 22nd Annual World Congress on Anti-Aging …

Orlando, FL (PRWEB) May 13, 2014

Neil Riordan, PhD will Present Umbilical Cord Mesenchymal Stem Cells (MSC) in the Treatment of Autoimmune Diseases at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as part of the Specialty Workshop: Stem Cells in Anti-Aging Medicine: An Update.

The primary focus of this workshop is to teach medical professionals how to successfully incorporate stem cell treatments into their practices. Expert faculty will cover stem cell theory and clinical trial research for all aspects of regenerative medicine as well as stem cell treatment marketing.

Dr. Riordan will discuss: Allogeneic mesenchymal stem cells mechanisms of immune modulating activities; the importance of MSC placement for clinical effect; human clinical trials demonstrating efficacy; alternative routes of MSC delivery; dose and frequency; and clinical safety of MSC.

The conference will be held from May 15 17, 2014 at the Gaylord Palms Hotel in Orlando, Florida. For more information, please visit http://www.a4m.com/anti-aging-conference-orlando-2014-may.html.

About Neil Riordan PhD

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI's stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor listed on more than 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Original post:
Neil Riordan, PhD Presents at American Academy of Anti-Aging Medicine's 22nd Annual World Congress on Anti-Aging ...

Stem cell treatments reaching patients

Neurosurgeon and stem cell researcher, Joseph Ciacci M.D. will soon start a clinical trial of stem cells to treat paralysis from spinal cord injury.

After many years of waiting, a flood of new regenerative-cell therapies is finally reaching patients. Hundreds of clinical trials for these experimental treatments are under way across the world.

In the United States, 774 trials with stem or other regenerative cells are open to patients or soon will be, according to clinicaltrials.gov, which lists government-approved clinical testing in this country and abroad. Of that total, 147 are taking place in California.

One of the most difficult tests involving stem cells repairing spinal-cord damage that has caused complete loss of movement and sensation below the injury site is set to begin soon at UC San Diego.

Patients in that study will get injections of fetal-derived neural stem cells in and around the injury site, along with physical therapy and immune-system drugs in case theres a reaction to the stem cells. The trial will use a device that delivers precisely targeted micro-injections of cells to the targeted areas.

The clinical trial will test safety and look for early signs of efficacy, said Dr. Joseph Ciacci, a UC San Diego neurosurgeon leading the testing.

A study published a year ago found that in rats with spinal-cord injuries, the neural stem cells significantly improved movement in the hind paws. Ciacci, who co-authored that study, saw the cells proliferate and fill in a spinal-cord cavity that had resulted from the injuries. Such results supported testing the therapy in people, he said, but he declined to say whether he expected to see any improvement in those patients.

I really dont know, because its not been done, Ciacci said.

The clinical trial is expected to start in June. Its intended for adults 18 to 65 years old who suffered their injury at least one year ago but no more than two years ago. For more information, visit utsandiego.com/ucsdspinal or call Amber Faulise at (858) 657-5175.

Another type of stem cells, mesenchymal stromal, might be described as the duct tape of regenerative cells. Generally derived from bone marrow, they are being tested for treatment of pulmonary fibrosis, multiple sclerosis, kidney transplants, liver cirrhosis, osteoarthritis of the knee, stroke and many other conditions. Worldwide, 226 trials are being conducted with these cells, including 45 in the U.S. and 12 in California, according to clinicaltrials.gov.

See original here:
Stem cell treatments reaching patients

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory …

We did this randomised, open-label, phase 2 study at seven German transplantation centres. We enrolled patients with aggressive B-cell or T-cell lymphoma and primary refractory disease, early relapse (2), busulfan (12 mg/kg oral or 96 mg/kg intravenous), and cyclophosphamide (120 mg/kg) was followed by allogeneic stem-cell transplantation. Patients were randomly assigned (1:1) to receive rituximab (375 mg/m2 on days 21, 28, 35, 42, 175, 182, 189, and 196) or not. Allocation was done with a centralised computer-generated procedure; patients were stratified by histological subtype (B-cell vs T-cell lymphoma) and donor match (HLA-identical vs non-identical). Neither investigators nor patients were masked to allocation. The primary endpoints were the incidence of acute graft-versus-host disease grade 24 in each treatment group and overall survival at 1 year in both groups combined. All analyses were done for the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00785330.

More:
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory ...

First stem cell trial for stroke shows lasting benefits

People who received the world's first stem cell treatment for strokes have shown measurable reductions in disability and handicap a year after the injection into their damaged brains.

Some can move limbs and manage everyday tasks that were impossible before they received an injection of neural progenitor stem cells, which were clones of cells originally taken from the cortex of a donated fetus.

Apart from physical rehabilitation, there are few treatments for people left severely disabled by a stroke. Demand for more options is high, with 800,000 new cases each year in the US and 150,000 in the UK.

"We're encouraged, and it's a nice progressive piece of news," says Michael Hunt, the chief executive officer of ReNeuron, the company in Guildford, UK, that developed the treatment. "We must be circumspect, but we are seeing what seems to be a general trend towards improvement in a disparate group of patients," he says.

ReNeuron presented its latest results on the first 11 patients on 7 May in Nice, France, at the 23rd European Stroke Conference. They build on interim findings released last year.

The patients in the PISCES trial (Pilot Investigation of Stem Cells in Stroke) had all suffered their strokes at least six months before treatment and were all chosen because their symptoms had plateaued, making any improvements more likely to be the result of treatment.

There were improvements in median scores on all five scales used to measure the patients' recovery.

On a score that measures quality of life from 0 to 100, patients began with a median score of 45, but within a year this had risen by 18 points, a 40 per cent improvement.

Rankin Scores, which grade disability and handicap from healthy (0) to dead (6) improved from a median of 3 at the start to 2 for four of the patients, although the rest remained the same. "That's equivalent to taking a patient down a whole level of dependency, and equates to a 20 per cent improvement," says Hunt. Scores on all the other three scales were higher at 12 than at three months, suggesting the improvements were continuing.

The company is now actively recruiting for a second, larger trial in 41 people. They will be recruited sooner after their strokes within two to three months in the hope that earlier treatment will prevent some of the irreversible scarring. It will also deploy a harder but more objective measure of improvement in which patients have to try lifting a wooden block onto a platform. Hunt expects full results by the end of 2015.

Read more:
First stem cell trial for stroke shows lasting benefits

Son's successful stem cell transplant best Mother's Day present

NASHVILLE, Tenn. - Carrie Yokley and her family stayed at the Ronald McDonald House in Nashville while her son Ryan received lifesaving treatment.

On Friday afternoon, Yokley said her prayers were answered. Doctorssaid her sons stem cell transplant was a success, curing him of two diseases, Burton's and Crohn's.

She said that is the best Mothers Day gift she could have hoped for.

You think your kids are the best gift you can get, but then you get a gift like this, [he gets] a second chance to be a little boy, said Yokley.

Carrie Yokley will celebrate Mothers Day at the Ronald McDonald House, along with 32 other mothers going through a similar experience.

It's just a nice time for them to put aside the worries they have about their child's illness and celebrate being a mother and getting to be with their children, said Heather Powell, with the Ronald McDonald House Charities.

Ryan cannot be around other people until his immune system improves. Yokley said Ryan felt bad that he could not do more with his mother on the special day.

She assured him, this Mothers Day she received everything she wanted.

I said we're together, I have you all, that's the best Mother's Day present ever, said Yokley.

The Ronald McDonald House Charities of Nashville provides a home away from home for families of critically ill children receiving care at Nashville area hospitals.

Continued here:
Son's successful stem cell transplant best Mother's Day present

Former Professional Football Player to Be a Spokesperson for Smartchoice Stem Cell Institute to Promote Adult Stem …

Jacksonville, FL (PRWEB) May 09, 2014

Tom McManus, former professional football player with the Jacksonville Jaguars is teaming up with SmartChoice Stem Cell Institute as a spokesperson. He and SmartChoice hope that the alliance will promote awareness of benefits and success of Adult Stem Cell procedures as non-surgical treatment for sports injuries, arthritis, joint and back pain.

McManus, who was a middle linebacker for the Jacksonville Jaguars, is a firm believer in the treatment. I think SmartChoice procedures are a great alternative to invasive surgery and want to let people know that this option exists in Jacksonville. Many athletes have been going to Germany for these types of treatments, and now they dont have to leave the United States.

SmartChoice Stem Cell Institute, SmartChoiceStemCell.com, located in Jacksonville, Florida, was founded by Dr. Hardesh Garg, M.D. Dr. G, as he is affectionately referred by his patients, has been practicing medicine for over 20 years but has focused his medical practice on Adult Stem Cells for almost five years. Regenerative Medicine and Adult Stem Cell treatments are the newest alternative to invasive orthopedic surgeries for joint problems and sports injuries. This is the future and we are honored to have Tom as our spokesperson as we move forward in this exciting medical field.

SmartChoice Adult Stem Cell Procedures use adult stem cells from a patients own body, harvested and injected in a same-day office procedure to regenerate and rejuvenate injured cells. These procedures are helpful not only for sports injuries, but also for arthritis and other joint and back problems.

Dr. Garg and McManus hope that this partnership will increase public awareness of SmartChoice Adult Stem Cell procedures. SmartChoice continues to help patients with a variety of sports injuries. McManus will use his NFL and public speaking experience to help Dr. Garg treat athletes with sports injuries, both amateur and professional, especially the ever-growing golf community in Florida and other states.

For more information about this topic, or to schedule an interview with Dr. Garg, please visit SmartChoiceStemCell.com or call Brooke Williams, Chief Clinical Consultant, at 904-997-6100 or email Brooke at consultant(at)smartchoicestemcell(dot)com

See original here:
Former Professional Football Player to Be a Spokesperson for Smartchoice Stem Cell Institute to Promote Adult Stem ...

Stem Cell News | Stem Cell Treatment, Stem Cell Research …

In a study published today inF1000Research, Professor Kenneth Lee of the Chinese University of Hong Kong reveals the full experimental results of an attempt to replicate a controversial study published inNaturerecently that suggested that bathing somatic cells in acid can reprogram them to induced pluripotent stem cells (iPS cells). With systematically collected and fully available data, Lee and his colleagues report that carefully replicating the original acid-treatment method does not induce pluripotency in two types of mouse somatic cells, including those used in the original study.

Read the story

A subset of immune cells directly target colon cancers, rather than the immune system, giving the cells the aggressive properties of cancer stem cells.

Read the story

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.

Read the story

A new study inNaturechallenges research data that form the scientific basis of clinical trials in which heart attack patients are injected with stem cells to try and regenerate damaged heart tissue.

Read the story

By carefully controlling the levels of two proteins, researchers at theSalk Institutehave discovered how to keep mammary stem cellsthose that can form breast tissuealive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

Read the story

See the rest here:
Stem Cell News | Stem Cell Treatment, Stem Cell Research ...

New Jersey Stem Cell Therapy | Stem Cell Treatments

New Jersey Stem Cell Therapy Worldstemcells.com is one of the leading stem cell therapy and treatment providers for residents of New Jersey and across the nation. Our cutting edge technology and compassionate staff truly set us apart from the competition. We are a US based company that understands your needs and concerns when looking for a stem cell treatment center. Our treatment center is located in Cancun, Mexico.

Conditions we treat include but not limited to:

Getting Started With Your Stem Cell Therapy and Treatments Here at World Stem Cells LLC we try to make the process of receiving stem cell transplants as easy as possible. We will help you figure out what your needs are and help you reach your goals as fast as possible. Follow the steps below on what to do.

Option 1 1.) Go to any page on our website and fill out the contact form. 2.) Fill in the required information and select the condition you would like to treat with stem cell therapy. 3.) Be sure to include any special information in the comments section. 4.) Click the submit button and we will contact you in a timely manner. 5.) Thats it, youre done!!!

REQUEST INFORMATION NOW!

Option 2

Call 800-234-1693 and speak with a representative regarding your stem cell therapy needs and requirements.

Read the original:
New Jersey Stem Cell Therapy | Stem Cell Treatments

Stem Cell Treatments – Stemgenex

For thousands of years physicians had 3 ways to treat patients; with surgery, drugs, and medical devices. These were considered the 3 pillars of medicine and society has benefited from major advances in these areas. Today, a 4th pillar of medicine, cellular based therapies or regenerative medicine is likely to dominate medical therapies in the future. Regenerative medicine uses the bodys own cells to treat diseases, repair damage, and restore structure and function.

We understand what it means to seek a good healthy quality of life and our doctors are focused on making positive differences in the lives of patients through innovative stem cell treatments and regenerative medicine treatments.

And it just so happens that you came equipped with stem cells, The Human Repair Kit and we know how to put it to work.

A 150-Year History of Autologous Treatments in Western Medicine There has not been a more powerful method in existence of healing the body than by using its own biology and chemistry. Skin grafting, which is the use of skin or a skin substitute to replace a non-healing wound, has been in existence since 800 BC. One of the earliest documented cases of attempted skin grafting occurred in India. The first successful autologous skin graft occurred in 1822.

(Information provided by Kate A. Lygoe , BSc, and Mark P. Lewis, PhD. Eastman Dental Institute, University College London)

Multiple Sclerosis Stem Cell Treatment

MS is a degenerative disease that involves the deterioration of nerve cells. Our Stem cell treatment and stem cell therapy works by resetting the patient's immune system through the use of stem cells. This Multiple Sclerosis stem cell therapy has helped patients who don't respond to typical drug treatment.

Learn More >>>

Alzheimer's Stem Cell Treatment

In a healthy brain, there are over 100 billion nerve cells connected to extensions. With the onset of Alzheimers disease, information transfer at the synapses (the connection between the nerve cells and extensions) starts to break down, and the number of synapses decreases significantly.

See the rest here:
Stem Cell Treatments - Stemgenex

$4 Million from Eli and Edythe Broad Foundation Will Support UCLA Research

Contact Information

Available for logged-in reporters only

Newswise Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers.

The gifts bring to $30 million The Broad Foundation's total support of faculty recruitment and basic and translational research at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and at the Center for Inflammatory Bowel Diseases at UCLA's Division of Digestive Diseases.

A $2 million gift to the Broad Stem Cell Research Center adds to The Broad Foundation's original 2007 gift of $20 million, which has supported faculty and research and launched the Innovation Award program, which furthers cutting-edge research at the center by giving UCLA stem cell scientists "seed funding" for their research projects. The new gift will enable the continuation of the award program, which has yielded a 10-to-1 return on investment with grantees securing additional funding from other agencies, including the National Institutes of Health and more than $200 million in total grants from the California Institute for Regenerative Medicine, the state's stem cell agency.

"The Broads' generous support has been essential to the development of new therapies that are currently in, or very near, clinical trials for treating blindness, sickle cell disease and cancer," said Dr. Owen Witte, director of the Broad Stem Cell Research Center. "The Broad Stem Cell Research Center's work, supported by critical philanthropic and other resources, is quickly being translated from basic scientific discoveries into new cellular therapies that will change the practice of medicine and offer future treatment options for diseases thought to be incurable, such as muscular dystrophy, autism and AIDS."

The $2 million gift to the Division of Digestive Diseases builds on nearly $6 million in previous commitments from The Broad Foundation since 2003.

The gifts have enabled the division to develop a comprehensive research and clinical enterprise focused on inflammatory bowel disease, one of only a few such centers in the world. Earning a multifold return for The Broad Foundation's initial investments, these grants have enabled investigators to secure $11 million in funding from pharmaceutical companies, the National Institutes of Health and nonprofit foundations.

In addition, The Broad Foundation's Broad Medical Research Program has provided more than $600,000 in grants to UCLA researchers over the past decade for the study of inflammatory bowel disease.

The new gift will support the Center for Inflammatory Bowel Diseases and research led by Dr. Charalabos "Harry" Pothoulakis, the center's director. Pothoulakis' team conducts research aimed at identifying the molecular mechanisms involved in the development of this group of chronic debilitating diseases, for which there is no cure.

See the article here:
$4 Million from Eli and Edythe Broad Foundation Will Support UCLA Research